Gitterman Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Gitterman Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-845	Closed	-$297K	–	105
2023 Q2	$297K	Sell	845 -343	-29%	-$116K	0.14%	43
2023 Q1	$374K	Buy	+1,188	New	+$356K	0.18%	26
2022 Q4	–	Sell	-768	Closed	-$221K	–	93
2022 Q3	$221K	Sell	768 -105	-12%	-$30.2K	0.23%	54
2022 Q2	$249K	Sell	873 -344	-28%	-$92.1K	0.23%	48
2022 Q1	$318K	Buy	+1,217	New	+$289K	0.26%	47

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gitterman Wealth Management's VRTX Position: Q3 2023 in Review

Gitterman Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 845 shares — an estimated $297K sold.

Gitterman Wealth Management first reported a position in VRTX in Q1 2022 and held it in 5 quarters. The position peaked at $374K in Q1 2023. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

Gitterman Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Gitterman Wealth Management sold 845 Vertex Pharmaceuticals shares in Q3 2023, an estimated $297K.
Gitterman Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2022 and held it in 5 quarters.
Gitterman Wealth Management's Vertex Pharmaceuticals position peaked at $374K in Q1 2023.
1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Gitterman Wealth Management's 13F filing for Q3 2023, filed 2 Nov 2023.